ESR1 and breast cancer: Moreover, the overexpression of DSCAM-AS1 in tamoxifen-resistant cell line models, which also overexpress ESR1, highlights the potential role of DSCAM-AS1 in endocrine therapy resistance in breast cancer [15, 26, 40].